Unit of Dental Hygiene - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia
Pavia, Lombardy, 27100, Italy
NCT Number: NCT06311253
The aim of the study is to assess the effect of lactoferrin in LBC complex can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients.
Interested in participating?
Request Info18 year–40 year
All sexes
Interventional
Not applicable
Pavia, Lombardy, 27100, Italy
The aim of the study is to assess the effect of lactoferrin in LBC complex can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients. Patients' enrollment will be conducted according to inclusion criteria.
At the first visit, periodontal parameters will be recorded: Plaque Index (PI), recession (R) Bleeding on Probing (BoP), modified Marginal Gingival Index (mMGI), Papillary Marginal Gingival (PMGI), Plaque Control Record ( PCR %), Approximal Plaque Index (API), Clinical Attachment loss (CAL) and Probing Pocket Depth (PPD).
Professional debridement will be conducted with piezoelectric instrumentation and air-flow administration with glycine powders.
Subsequently, patients will be randomly divided into two groups:
Professional debridement will be repeated every 3 months. Periodontal indexes evaluation will be conducted at the baseline (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily use of Emoform Glic toothpaste twice a day during home oral hygiene
Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
Time frame: Baseline, 1, 3 and 6 months
Distance (in mm) between the gingival margin and the amelo-cemental junction.
Time frame: Baseline, 1, 3 and 6 months
Scoring criteria:
0 = no plaque;
Time frame: Baseline, 1, 3 and 6 months
Site-specific assessment of the presence or absence of gum bleeding after the insertion of the periodontal probe for the detection of PPD, detected on 6 sites.
Percentage of sites with bleeding on probing determines the BOP%.
Time frame: Baseline, 1, 3 and 6 months
Evaluation (in mm) of the depth of the gingival sulcus, through a millimeter periodontal probe; it is detected from the gingival margin to the bottom of the gingival sulcus or periodontal pocket, evaluated at 6 sites.
Time frame: Baseline, 1, 3 and 6 months
Scoring criteria:
0 = Absence of inflammation
Time frame: Baseline, 1, 3 and 6 months
Numerical score from 0 to 3 of gingival inflammation. Papille and gingival margins (vestibular and lingual) are given a score from 0 to 3. The score is given by the total amount of inflamed sites on the total of examined sites.
Time frame: Baseline, 1, 3 and 6 months
% assessment of the amount of plaque on dental surfaces; it is detected on 4 surfaces: distal, mesial, vestibular, lingual / palatal. The number of sites with plaque is divided by the total number of sites available in the mouth and multiplied by 100. Results indicate the index as a percentage.
Time frame: Baseline, 1, 3 and 6 months
Measurement (in mm) of the position of the gingival margin in relation to the cemento-enamel junction (CEJ).
University of Pavia
Other
Non-surgical Periodontal Treatment With Adjunctive Use of Lactoferrin Contained in Toothpaste and Mouthwash: Randomized Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07688421
Dental Implant Failed, Mouth Diseases
Guarulhos, São Paulo, Brazil
View Trial DetailsNCT07615361
Alveolar Bone Loss, Bone Diseases
Istanbul, Uskudar, Turkey (Türkiye)
View Trial DetailsNCT07573761
Alveolar Bone Loss, Bone Diseases
Istanbul, Uskudar, Turkey (Türkiye)
View Trial DetailsNCT07367737
Mouth Diseases, Periodontal Diseases
Baghdad, Medical City, Iraq
View Trial Details